Research Project 1: Role of the Aromatic Hydrocarbon Receptor in the Etiology of

研究项目1:芳香烃受体在病因学中的作用

基本信息

  • 批准号:
    8143314
  • 负责人:
  • 金额:
    $ 21.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-15 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

Known breast cancer risk factors do not completely explain the increase in breast cancer incidence in the U.S. since 1940. It has been suggested that environmental chemicals, including polycyclic aromatic hydrocarbons (PAH), have played a role in human breast cancer. PAH-induced tumorigenesis is initiated through the AhR, an evolutionary conserved transcription factor activated by ubiquitous environmental pollutants. In the original PO1, we proposed the novel hypothesis that the AhR plays an important role in malignant epithelial cell growth in part through interaction with the Wnt/CK2 and NF-xB signaling pathways. Collaborative studies with Drs. Sonenshein and Seldin have strongly supported this hypothesis and have provided new evidence suggesting an important role for the AhR in tumor progression as well. Consequently, a new hypothesis is proposed: As mammary epithelial cells progress from normal to immortalized cells and then to invasive tumors, AhR activity is modified through interactions with environmental chemicals, other transcription factors, and cofactors to differentially regulate target gene transcription and to effect changes in cell growth and invasiveness. Three aims are proposed: 1) Assess AhR-mediated tumor invasion in vitro: AhR regulation of cell invasion in 3-dimensional cultures and the potential for the AhR to influence invasiveness through modulation of Slug will be evaluated. Collaborative studies will assess the role of AhRCK2 interactions in tumor invasiveness. These mechanistic studies will provide the basis for complementary studies evaluating tumor invasion in vivo. 2) Map differential cofactor recruitment by constitutively active AhR: Studies will quantify binding of the AhR to regulatory elements within genes differentially regulated by the AhR and will reveal the spectrum of coregulators recruited by constitutively active and chemical-activated AhR in cells representing different levels of malignancy. Collaborative studies will evaluate AhR-NF-KB interactions that may influence AhR activity. 3) Define the functional consequences of constitutively active AhR in vivo: Stable cell lines in which AhR activity has been modulated (Aim 1), will be exploited in a xenograft mammary tumor model to study the role of the AhR in mammary tumor cell growth in situ. The contribution of enforced AhR expression in mammary epithelial cells also will be evaluated with MMTV-AhR transgenic mice. Evidence of AhR contributions to tumor growth and invasion provided by these studies would link environmental exposures to tumor aggressiveness and would strongly encourage translational studies with selective AhR inhibitors. New information will be obtained on AhR function in normal as compared with malignant cells, on differential control of gene transcription by the AhR, and on the molecular and functional outcomes of constitutively activated as compared with environmental chemical-activated AhR. The results will help place AhR function in the continuum of malignant transformation and will further expand on our central theme of biologically significant interactions between AhR, CK2 and NF-KB during mammary tumorigenesis.
已知的乳腺癌危险因素并不能完全解释乳腺癌发病率的增加 美国自 1940 年起就已开始使用环境化学品,包括多环芳烃 碳氢化合物(PAH)在人类乳腺癌中发挥了作用。 PAH 诱导的肿瘤发生开始 通过 AhR,一种由普遍存在的环境激活的进化保守转录因子 污染物。在最初的 PO1 中,我们提出了新的假设,即 AhR 在 恶性上皮细胞的生长部分是通过与 Wnt/CK2 和 NF-xB 信号通路的相互作用来实现的。 与博士的合作研究。 Sonenshein 和 Seldin 强烈支持这一假设并 提供了新的证据表明 AhR 在肿瘤进展中也发挥着重要作用。最后, 提出了一个新的假设:随着乳腺上皮细胞从正常细胞发展为永生化细胞, 然后对于侵袭性肿瘤,AhR 活性通过与环境化学物质、其他物质的相互作用而改变 转录因子和辅助因子差异调节靶基因转录并影响 细胞生长和侵袭性。提出了三个目标:1) 体外评估 AhR 介导的肿瘤侵袭: AhR 对 3 维培养物中细胞侵袭的调节以及 AhR 影响的潜力 将评估通过调节 Slug 的侵入性。合作研究将评估 AhRCK2 的作用 肿瘤侵袭力中的相互作用。这些机制研究将为互补性研究提供基础 评估肿瘤体内侵袭的研究。 2) 通过组成型活性映射差异辅因子招募 AhR:研究将量化 AhR 与受不同基因调控的基因内调控元件的结合。 AhR 并将揭示由组成型活性和化学激活招募的辅助调节器的谱 细胞中的 AhR 代表不同程度的恶性肿瘤。合作研究将评估 AhR-NF-KB 可能影响 AhR 活动的相互作用。 3) 定义本构活跃的功能后果 AhR 体内:AhR 活性已被调节的稳定细胞系(目标 1)将被用于 异种移植乳腺肿瘤模型研究 AhR 在乳腺肿瘤细胞原位生长中的作用。这 乳腺上皮细胞中强制 AhR 表达的贡献也将通过 MMTV-AhR 进行评估 转基因小鼠。这些研究提供了 AhR 对肿瘤生长和侵袭贡献的证据 将环境暴露与肿瘤侵袭性联系起来,并强烈鼓励转化 选择性 AhR 抑制剂的研究。正常情况下,将获得有关 AhR 功能的新信息: 与恶性细胞相比,AhR 对基因转录的差异控制以及分子 与环境化学激活的 AhR 相比,组成型激活的功能结果。 该结果将有助于将AhR功能置于恶性转化的连续体中,并将​​进一步扩展 关于我们的中心主题,即乳腺发育过程中 AhR、CK2 和 NF-KB 之间具有生物学意义的相互作用 肿瘤发生。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David H Sherr其他文献

David H Sherr的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David H Sherr', 18)}}的其他基金

Endogenous and Environmental AHR Ligands in Head and Neck Cancer Aggression and Immunosuppression
头颈癌侵袭和免疫抑制中的内源性和环境 AHR 配体
  • 批准号:
    9922302
  • 财政年份:
    2019
  • 资助金额:
    $ 21.64万
  • 项目类别:
Endogenous and Environmental AHR Ligands in Head and Neck Cancer Aggression and Immunosuppression
头颈癌侵袭和免疫抑制中的内源性和环境 AHR 配体
  • 批准号:
    9752872
  • 财政年份:
    2019
  • 资助金额:
    $ 21.64万
  • 项目类别:
CHARACTERIZATION OF AHR COMPLEX IN MALIGNANT TUMOR CELLS
恶性肿瘤细胞中 AHR 复合物的表征
  • 批准号:
    8365505
  • 财政年份:
    2011
  • 资助金额:
    $ 21.64万
  • 项目类别:
How environmental chemicals impair immunity
环境化学物质如何损害免疫力
  • 批准号:
    7909634
  • 财政年份:
    2009
  • 资助金额:
    $ 21.64万
  • 项目类别:
Research Project 1: Role of the Aromatic Hydrocarbon Receptor in the Etiology of
研究项目1:芳香烃受体在病因学中的作用
  • 批准号:
    7522897
  • 财政年份:
    2008
  • 资助金额:
    $ 21.64万
  • 项目类别:
High Performance Research Flow Cytometer
高性能研究流式细胞仪
  • 批准号:
    7217177
  • 财政年份:
    2007
  • 资助金额:
    $ 21.64万
  • 项目类别:
CHARACTERIZATION OF AHR COMPLEX IN MALIGNANT TUMOR CELLS
恶性肿瘤细胞中 AHR 复合物的表征
  • 批准号:
    6978482
  • 财政年份:
    2004
  • 资助金额:
    $ 21.64万
  • 项目类别:
AH RECEPTOR/TRANSCRIPTION FACTOR AS A REGULATOR OF HYDROCARBON BIOACTIVITY
AH 受体/转录因子作为碳氢化合物生物活性的调节剂
  • 批准号:
    6578799
  • 财政年份:
    2002
  • 资助金额:
    $ 21.64万
  • 项目类别:
Novel strategy for AL amyloid immunotherapy
AL 淀粉样蛋白免疫治疗的新策略
  • 批准号:
    6590088
  • 财政年份:
    2002
  • 资助金额:
    $ 21.64万
  • 项目类别:
AH RECEPTOR/TRANSCRIPTION FACTOR AS A REGULATOR OF HYDROCARBON BIOACTIVITY
AH 受体/转录因子作为碳氢化合物生物活性的调节剂
  • 批准号:
    6664575
  • 财政年份:
    2002
  • 资助金额:
    $ 21.64万
  • 项目类别:

相似海外基金

Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 21.64万
  • 项目类别:
Dissecting Phenotype Switching in Early Stage Melanomas
剖析早期黑色素瘤的表型转换
  • 批准号:
    10676721
  • 财政年份:
    2022
  • 资助金额:
    $ 21.64万
  • 项目类别:
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
球形核酸纳米结构作为一流的 cGAS 激动剂,用于胶质母细胞瘤的免疫治疗。
  • 批准号:
    10539146
  • 财政年份:
    2022
  • 资助金额:
    $ 21.64万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 21.64万
  • 项目类别:
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
球形核酸纳米结构作为一流的 cGAS 激动剂,用于胶质母细胞瘤的免疫治疗。
  • 批准号:
    10709540
  • 财政年份:
    2022
  • 资助金额:
    $ 21.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了